Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Experimental Data Snapshot

  • Resolution: 1.94 Å
  • R-Value Free: 0.222 
  • R-Value Work: 0.175 

wwPDB Validation   3D Report Full Report

Currently 6UT0 does not have a validation slider image.

This is version 1.2 of the entry. See complete history


Identification of the Clinical Development CandidateMRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer.

Fell, J.B.Fischer, J.P.Baer, B.R.Blake, J.F.Bouhana, K.Briere, D.M.Brown, K.D.Burgess, L.E.Burns, A.C.Burkard, M.R.Chiang, H.Chicarelli, M.J.Cook, A.W.Gaudino, J.J.Hallin, J.Hanson, L.Hartley, D.P.Hicken, E.J.Hingorani, G.P.Hinklin, R.J.Mejia, M.J.Olson, P.Otten, J.N.Rhodes, S.P.Rodriguez, M.E.Savechenkov, P.Smith, D.J.Sudhakar, N.Sullivan, F.X.Tang, T.P.Vigers, G.P.Wollenberg, L.Christensen, J.G.Marx, M.A.

(2020) J Med Chem 63: 6679-6693

  • DOI: https://doi.org/10.1021/acs.jmedchem.9b02052
  • Primary Citation of Related Structures:  
    6USX, 6USZ, 6UT0

  • PubMed Abstract: 

    Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRAS G12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRAS G12C is described.

  • Organizational Affiliation

    Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
GTPase KRas
A, B, C, D
170Homo sapiensMutation(s): 4 
UniProt & NIH Common Fund Data Resources
Find proteins for P01116 (Homo sapiens)
Explore P01116 
Go to UniProtKB:  P01116
PHAROS:  P01116
GTEx:  ENSG00000133703 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP01116
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
M1X (Subject of Investigation/LOI)
Query on M1X

Download Ideal Coordinates CCD File 
G [auth A],
J [auth B],
M [auth C],
P [auth D]
C32 H37 Cl F N7 O2
Query on GDP

Download Ideal Coordinates CCD File 
E [auth A],
H [auth B],
K [auth C],
N [auth D]
C10 H15 N5 O11 P2
Query on MG

Download Ideal Coordinates CCD File 
F [auth A],
I [auth B],
L [auth C],
O [auth D]
Experimental Data & Validation

Experimental Data

  • Resolution: 1.94 Å
  • R-Value Free: 0.222 
  • R-Value Work: 0.175 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 74.918α = 90
b = 61.8β = 111.37
c = 76.05γ = 90
Software Package:
Software NamePurpose
iMOSFLMdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report

Currently 6UT0 does not have a validation slider image.

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2020-04-22
    Type: Initial release
  • Version 1.1: 2020-07-22
    Changes: Database references
  • Version 1.2: 2023-10-11
    Changes: Data collection, Database references, Derived calculations, Refinement description